Rare diseases dominate catalysts for the smallest companies
Our final look at third-quarter events focuses this time on the smallest players, with data from Amryt, Ovid, Bellus and more.
First fragile X test is approved, and Zynerba could benefit
The fragile X pipeline is strewn with failures, and crunch time is approaching for Zynerba’s cannabinoid.
Biotech floats come back with a vengeance
The biotech IPO market records its first billion dollar quarter in two years as demand for new issues recovers.
